Effects of pioglitazone on bone formation and resorption markers in type 2 diabetes mellitus.

Effects of pioglitazone on bone formation and resorption markers in type 2 diabetes mellitus. - Effects of pioglitazone on bone

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023805

Enrollment

Registered

2016-08-29

Start date

2010-01-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus.

Interventions

pioglitazone group(males 30 mg/day, females 15 mg/day) 3months metformin group(750 mg/day) 3months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The subjects of this research were male and female type 2 diabetes patients, aged less than 80 years, who attended the First Department of Medicine at the University of Occupational and Environmental Health, Japan, and its associated centers between January 2010 and March 2012.

Exclusion criteria

Exclusion criteria: Patients treated with pioglitazone, metformin or insulin, with type 1 diabetes, history of secondary osteoporosis, heart failure, renal failure, liver failure, and patients receiving any drugs that affect bone metabolism (bisphosphonates, vitamin K, estrogen, calcium, anabolic steroids, or male and female hormones) were excluded from the research.

Design outcomes

Primary

Measure	Time frame
The primary endpoint was changes in bone resorption markers after 3 months by pioglitazone.	—

Countries

Japan

Contacts

Public ContactHiroko Mori

University of Occupational and Environmental Health, Japan First Department of Internal Medicine, School of Medicine

morihiro@med.uoeh-u.ac.jp093-603-1611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026